![]() Vicki Goodman, vice president, oncology clinical research, Merck Research Laboratories. The long-term data from KEYNOTE-021 (Cohort G) reinforce the use of KEYTRUDA in combination with chemotherapy in certain advanced lung cancer patients, while data from our oncology pipeline reflect our commitment to exploring a number of new combinations with KEYTRUDA that we believe could have a meaningful impact for more lung cancer patients,” said Dr. “Over the last five years, KEYTRUDA has become foundational in the treatment of metastatic lung cancer. Additionally, updated follow-up data from a Phase 1/2 study of quavonlimab in combination with KEYTRUDA showed encouraging anti-tumor activity and an acceptable safety profile as first-line treatment in patients with advanced NSCLC (Poster #TS01.02). These findings represent the longest follow-up data for an anti-PD-1/PD‑L1 therapy in combination with chemotherapy for the first-line treatment of NSCLC. Patients in Cohort G had no EGFR or ALK genomic tumor aberrations. 33%), progression-free survival (HR=0.54 ) and a sustained, long-term survival benefit (HR=0.71 ) versus chemotherapy alone (n=63) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) regardless of PD‑L1 expression (Featured Poster #OFP01.02). In KEYNOTE-021 (Cohort G), first-line treatment with KEYTRUDA in combination with chemotherapy (n=60) demonstrated a significant improvement in objective response rates (58% vs. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer clinical development program evaluating KEYTRUDA, Merck’s anti-PD-1 therapy: KEYTRUDA in combination with chemotherapy (KEYNOTE-021 ) and KEYTRUDA in combination with quavonlimab (MK-1308), Merck’s novel investigational anti-CTLA-4 antibody. Updated Data for Quavonlimab (MK-1308), a Novel Investigational Anti-CTLA-4 Antibody, in Combination With KEYTRUDA Were Presented Phase 3 Study for the Combination Planned in First-Line Advanced NSCLC ![]() New Long-Term Data From KEYNOTE-021 (Cohort G) Reinforce Use of KEYTRUDA in Certain Patients with Advanced Nonsquamous NSCLC
0 Comments
Leave a Reply. |